Esperion: Early Commercial Success Supports A Buy At These Prices [Seeking Alpha]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Seeking Alpha
SummaryEsperion's NEXLETOL and NEXLIZET are affordable, convenient, oral, once-daily, non-statin, LDL-C medicines recently approved by the FDA and European Commission. In addition, the company has reported impressive progress with payers.Esperion recently closed the biggest Japan development and commercial partnership with Otsuka Pharmaceutical. This brings the company's total current and future partnership payments to $1.5B.I believe the company's commercial progress and executive deals make ESPR a great speculative buy at these prices. I discuss how I intend to add to my ESPR position.Despite most of the world putting their attention towards COVID-19, cardiovascular disease is still the world-leading healthcare crisis. Esperion Therapeutics (I intend to review the company's commercial progress and why I am looking to buy ESPR in the near future. In addition, I describe my plans to add my undersized ESPR position.Commercial ProgressOn March 30th, Esperion launched NEXLETOL, and the c
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "strong-buy" rating.MarketBeat
- Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues [Yahoo! Finance]Yahoo! Finance
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
ESPR
Earnings
- 5/7/24 - Beat
ESPR
Sec Filings
- 5/8/24 - Form 8-K
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- ESPR's page on the SEC website